U.S Physical Therapy Research and Development Expenses 2010-2024 | USPH

U.S Physical Therapy research and development expenses from 2010 to 2024. Research and development expenses can be defined as an expense arising from studies and product development processes.
U.S Physical Therapy Annual Research and Development Expenses
(Millions of US $)
2024 $
2023 $
2022 $
2021 $
2020 $
2019 $
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
U.S Physical Therapy Quarterly Research and Development Expenses
(Millions of US $)
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
2023-03-31
2022-12-31
2022-09-30
2022-06-30
2022-03-31
2021-12-31
2021-09-30
2021-06-30
2021-03-31
2020-12-31
2020-09-30
2020-06-30
2020-03-31
2019-12-31
2019-09-30
2019-06-30
2019-03-31
2018-12-31
2018-09-30
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2017-06-30
2017-03-31
2016-12-31
2016-09-30
2016-06-30
2016-03-31
2015-12-31
2015-09-30
2015-06-30
2015-03-31
2014-12-31
2014-09-30
2014-06-30
2014-03-31
2013-12-31
2013-09-30
2013-06-30
2013-03-31
2012-12-31
2012-09-30
2012-06-30
2012-03-31
2011-12-31
2011-09-30
2011-06-30
2011-03-31
2010-12-31
2010-09-30
2010-06-30
2010-03-31
2009-12-31
2009-09-30
2009-06-30
2009-03-31
Sector Industry Market Cap Revenue
Medical Medical - Outpatient & Home Care $1.298B $0.605B
U.S. Physical Therapy, Inc. is the largest publicly-traded, pure-play operator of outpatient physical and occupational therapy clinics. The clinics provide pre- and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, rehabilitation of injured workers and preventative care. USPh also manages several physical therapy facilities for third parties, including physician groups. Each of USPh's clinics are directed by a licensed physical therapist that drive patient volume via local physicians, former patients and other referral sources. Marketing representatives are used to further augment sales. Historically, USPh has grown its business through de novo development; approximately two-thirds of USPh clinics were originally start-ups. Strategic acquisitions, which accelerate the Company's growth, are structured like the de novo partnerships, with significant ownership retained by founders.
Stock Name Country Market Cap PE Ratio
Fresenius SE (FSNUY) Germany $21.804B 0.00
Quest Diagnostics (DGX) United States $19.317B 19.51
DaVita (DVA) United States $11.363B 14.49
Encompass Health (EHC) United States $9.962B 22.32
Chemed (CHE) United States $8.236B 25.31
Elanco Animal Health (ELAN) United States $5.492B 13.07
Option Care Health (OPCH) United States $5.459B 25.87
RadNet (RDNT) United States $4.453B 98.62
Amedisys (AMED) United States $2.998B 21.34
LifeStance Health (LFST) United States $2.904B 0.00
Addus HomeCare (ADUS) United States $1.974B 22.91
Astrana Health (ASTH) United States $1.946B 26.61
Pennant (PNTG) United States $0.864B 34.93
Aveanna Healthcare Holdings (AVAH) United States $0.799B 0.00
Atai Life Sciences (ATAI) Germany $0.305B 0.00
Bioqual (BIOQ) United States $0.054B 0.00
Daxor (DXR) United States $0.036B 0.00
Ontrak (OTRK) United States $0.007B 0.00
MEDIROM Healthcare Technologies (MRM) Japan $0.004B 0.00
IMAC Holdings (BACK) United States $0.001B 0.00
Psychemedics (PMD) United States $0.000B 0.00